First-line targeted therapies for BRAF-V600-mutated and ROS1-rearranged NSCLC and second-line therapies for the EGFR exon 20 mutation, MET exon 14 skipping mutation, and RET rearranged NSCLC are approved by regulatory autorities; treatments for erbB2 and FGFR are still under investigation. This evidence concerns the gene EGFR and non-small cell lung carcinoma.